Published in Antimicrob Agents Chemother on July 01, 2004
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Comité de l'Antibiogramme de la Société Française de Microbiologie report 2003. Int J Antimicrob Agents (2003) 2.14
Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother (1991) 2.09
Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit (1998) 1.34
Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet (1990) 1.23
Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother (2000) 1.17
Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother (1995) 1.09
Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother (2003) 0.98
A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents (1994) 0.92
Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob Agents Chemother (1991) 0.91
Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother (1996) 0.90
Three-times weekly teicoplanin in the outpatient treatment of acute methicillin-resistant staphylococcal osteomyelitis: a pilot study. J Chemother (2002) 0.84
Management of serious staphylococcal infections in the outpatient setting. Drugs (1997) 0.83
Comparative pharmacokinetics of teicoplanin and vancomycin. J Chemother (2000) 0.81
Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers. Eur J Drug Metab Pharmacokinet (1991) 0.80
Does monastic life predispose to the risk of Saint Anthony's fire (herpes zoster)? Clin Infect Dis (2011) 2.56
Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 2.30
AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother (2003) 2.10
Macrophage activity in infected areas of an experimental vertebral osteomyelitis model: USPIO-enhanced MR imaging--feasibility study. Radiology (2008) 1.67
Macrophage imaging by USPIO-enhanced MR for the differentiation of infectious osteomyelitis and aseptic vertebral inflammation. Eur Radiol (2009) 1.58
Septic arthritis: monitoring with USPIO-enhanced macrophage MR imaging. Radiology (2011) 1.57
Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest (2005) 1.57
Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother (2004) 1.54
Multicenter evaluation of the MB/BACT system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2004) 1.44
Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents (2006) 1.10
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. Antimicrob Agents Chemother (2007) 1.07
Hospitalization of newborns and young infants for chickenpox in France. Eur J Pediatr (2010) 0.99
Real-time PCR assay for the detection and quantification of Legionella pneumophila in environmental water samples: utility for daily practice. Int J Hyg Environ Health (2007) 0.98
Legionella pneumophila Arthritis: use of medium specific for Mycobacteria for isolation of L. pneumophila in culture of articular fluid specimens. Clin Infect Dis (2002) 0.96
Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res (2005) 0.96
Surgical-site infection after cardiac surgery: incidence, microbiology, and risk factors. Infect Control Hosp Epidemiol (2005) 0.95
Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006. Clin Vaccine Immunol (2008) 0.92
MRI of macrophages in infectious knee synovitis. AJR Am J Roentgenol (2010) 0.90
Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med (2006) 0.89
Percutaneous inoculated rabbit model of intervertebral disc space infection: magnetic resonance imaging features with pathological correlation. Joint Bone Spine (2008) 0.88
Simultaneous determination of metronidazole and spiramycin I in human plasma, saliva and gingival crevicular fluid by LC-MS/MS. J Pharm Biomed Anal (2005) 0.87
Comparison of two RT-PCR methods for quantifying ampC specific transcripts in Escherichia coli strains. FEMS Microbiol Lett (2003) 0.86
Cellular magnetic resonance imaging for the differentiation of infectious and degenerative vertebral disorders: preliminary results. J Magn Reson Imaging (2009) 0.86
Prevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age. Clin Vaccine Immunol (2009) 0.85
Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides. PLoS One (2008) 0.83
Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. Antimicrob Agents Chemother (2003) 0.83
Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care (2006) 0.81
Molecular pharmacokinetics of catharanthus (vinca) alkaloids. J Clin Pharmacol (2007) 0.81
Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics. Antimicrob Agents Chemother (2012) 0.81
Increased resistance to beta-lactams in a Klebsiella pneumoniae strain: role of a deletion downstream of the Pribnow box in the blaSHV-1 promoter. Int J Antimicrob Agents (2006) 0.81
Ocular penetration of topically applied linezolid in a rabbit model. J Cataract Refract Surg (2010) 0.80
Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010-2011. BMC Public Health (2012) 0.79
Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics. Antimicrob Agents Chemother (2002) 0.79
Cateslytin, a chromogranin A derived peptide is active against Staphylococcus aureus and resistant to degradation by its proteases. PLoS One (2013) 0.79
Concentrations and in vivo antibacterial activity of spiramycin and metronidazole in patients with periodontitis treated with high-dose metronidazole and the spiramycin/metronidazole combination. J Antimicrob Chemother (2005) 0.79
State of the art: Could nursing mothers be vaccinated with attenuated live virus vaccine? Vaccine (2012) 0.78
Determination of fosmidomycin in human serum and urine by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.78
Efficacy of intravitreal administrations of linezolid in an experimental model of S. aureus-related endophthalmitis. Invest Ophthalmol Vis Sci (2012) 0.78
In vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pH. PLoS One (2013) 0.76
In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates. Antimicrob Agents Chemother (2003) 0.76
Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis. Curr Med Res Opin (2008) 0.76
In vivo macrophage imaging using MR targeted contrast agent for longitudinal evaluation of septic arthritis. J Vis Exp (2013) 0.75
Ocular penetration of linezolid after oral administration in rabbits. J Ocul Pharmacol Ther (2011) 0.75
Molecular determinants of fluoroquinolone antibacterial agents pharmacokinetics. Curr Clin Pharmacol (2009) 0.75
Relief of symptoms in patients with group A beta-hemolytic streptococcus tonsillopharyngitis: comparison between telithromycin and penicillin V. Scand J Infect Dis (2003) 0.75
The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. Anticancer Res (2003) 0.75